EP2473506A4 - Composés et compositions pour le traitement du cancer - Google Patents

Composés et compositions pour le traitement du cancer

Info

Publication number
EP2473506A4
EP2473506A4 EP10814469A EP10814469A EP2473506A4 EP 2473506 A4 EP2473506 A4 EP 2473506A4 EP 10814469 A EP10814469 A EP 10814469A EP 10814469 A EP10814469 A EP 10814469A EP 2473506 A4 EP2473506 A4 EP 2473506A4
Authority
EP
European Patent Office
Prior art keywords
compositions
compounds
treating cancer
cancer
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10814469A
Other languages
German (de)
English (en)
Other versions
EP2473506A2 (fr
Inventor
Michael Andrew Foley
Robert Gould
Peter Elliot
Anna Mandinova
Sam Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Canthera Therapeutics Inc
Original Assignee
General Hospital Corp
Canthera Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp, Canthera Therapeutics Inc filed Critical General Hospital Corp
Publication of EP2473506A2 publication Critical patent/EP2473506A2/fr
Publication of EP2473506A4 publication Critical patent/EP2473506A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86Oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
EP10814469A 2009-09-02 2010-09-02 Composés et compositions pour le traitement du cancer Withdrawn EP2473506A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27575409P 2009-09-02 2009-09-02
PCT/US2010/047615 WO2011028860A2 (fr) 2009-09-02 2010-09-02 Composés et compositions pour le traitement du cancer

Publications (2)

Publication Number Publication Date
EP2473506A2 EP2473506A2 (fr) 2012-07-11
EP2473506A4 true EP2473506A4 (fr) 2013-03-06

Family

ID=43625764

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10814469A Withdrawn EP2473506A4 (fr) 2009-09-02 2010-09-02 Composés et compositions pour le traitement du cancer

Country Status (9)

Country Link
EP (1) EP2473506A4 (fr)
JP (1) JP2013503888A (fr)
KR (1) KR20120104165A (fr)
CN (1) CN102625805A (fr)
AU (1) AU2010289493A1 (fr)
BR (1) BR112012004701A2 (fr)
CA (1) CA2772614A1 (fr)
IN (1) IN2012DN01878A (fr)
WO (1) WO2011028860A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101629642B1 (ko) 2014-06-25 2016-06-13 서울대학교산학협력단 피퍼롱구민을 유효성분으로 함유하는 지방간 예방용 식품 조성물, 지방간 치료용 약학 조성물, 지방간 치료용 동물 의약품 및 사료 조성물
GB201715008D0 (en) * 2017-09-18 2017-11-01 Inst De Medicina Molecular Faculdade De Medicina Univ De Lisboa TRPV2 Antagonists
KR20200081633A (ko) 2018-12-27 2020-07-08 주식회사 티에스디라이프사이언스 피퍼롱구민을 함유하는 담도폐쇄증 치료 또는 예방용 의약 조성물
CN110002987B (zh) * 2019-03-22 2020-09-15 南通大学 苯基亚烯丙基环己烯酮衍生物及制备方法和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102146054A (zh) * 2010-02-10 2011-08-10 新昌县来益科技开发有限公司 荜茇酰胺衍生物及其药物组合物和在制备抑制肿瘤生长的药物中的用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2117306A4 (fr) 2007-02-14 2010-02-10 Mars Inc Composés neurogéniques
WO2008112195A1 (fr) * 2007-03-09 2008-09-18 Bioseek, Inc. Méthodes d'identification d'agents et leur utilisation dans la prévention ou la stabilisation de la fibrose

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102146054A (zh) * 2010-02-10 2011-08-10 新昌县来益科技开发有限公司 荜茇酰胺衍生物及其药物组合物和在制备抑制肿瘤生长的药物中的用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HUANG: "A facile and highly stereoselective synthesis of (2E)-, (2E,4E)-unsaturated amides and related natural products", TETRAHEDRON LETTERS, vol. 28, no. 19, 1 January 1987 (1987-01-01), pages 2159 - 2162, XP055050870, DOI: 10.1016/S0040-4039(00)96069-6 *
See also references of WO2011028860A2 *

Also Published As

Publication number Publication date
IN2012DN01878A (fr) 2015-08-21
CA2772614A1 (fr) 2011-03-10
BR112012004701A2 (pt) 2018-06-12
WO2011028860A3 (fr) 2011-07-21
CN102625805A (zh) 2012-08-01
WO2011028860A2 (fr) 2011-03-10
AU2010289493A1 (en) 2012-04-19
EP2473506A2 (fr) 2012-07-11
KR20120104165A (ko) 2012-09-20
JP2013503888A (ja) 2013-02-04

Similar Documents

Publication Publication Date Title
IL218987A0 (en) Methods and compositions for treating cancer
HK1200363A1 (en) Compounds useful for treating cancer
HRP20160949T1 (hr) Novi sastavi i metode za liječenje karcinoma
EP2419136A4 (fr) Compositions et procédés destinés au traitement du cancer
EP2461835A4 (fr) Composition contenant des inhibiteurs de jarid1b et méthodes de traitement du cancer
EP2310006A4 (fr) Traitement du cancer
SG10201500124VA (en) Methods and Compositions for Treating Cancer
IL251083A0 (en) Compounds and preparations for the treatment of cancer
ZA201107879B (en) Composition for the treatment of prostate cancer
EP2504428A4 (fr) Procédés et compositions de traitement de maladies liées à l'oxalate
IL213398A0 (en) Compounds for treating cancer
IL214349A0 (en) Compositions and methods for the treatment of cancer
EP2437738A4 (fr) Procédés et compositions pour le traitement du cancer
GB0804496D0 (en) Treating cancer
EP2391211A4 (fr) Procédés et compositions de traitement d'un cancer du sein
EP2473506A4 (fr) Composés et compositions pour le traitement du cancer
EP2411031A4 (fr) Méthodes et compositions pour le traitement du cancer
EP2582384A4 (fr) Compositions et procédés de traitement du cancer
EP2537031A4 (fr) Compositions et méthodes pour le traitement du cancer
IL217764A0 (en) Methods and compositions for treating leukemia
GB0908537D0 (en) Compositions for treating tumours
GB0914322D0 (en) Compounds for treating cancer
GB0722030D0 (en) Compositions for treating tumours
SI3067054T1 (sl) Novi sestavki in postopki za zdravljenje raka
PT3067054T (pt) Novas composições e métodos para o tratamento de cancro

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120302

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MASSACHUSETTS GENERAL HOSPITAL

Owner name: CANTHERA THERAPEUTICS, INC.

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20130201

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/5377 20060101ALI20130128BHEP

Ipc: C07D 211/86 20060101AFI20130128BHEP

Ipc: A61K 31/4412 20060101ALI20130128BHEP

Ipc: A61P 35/00 20060101ALI20130128BHEP

17Q First examination report despatched

Effective date: 20131029

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140509